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DNA replicatione gene-mediated processes underlying sporadic Alzheimer's disease (AD), we
carried out a subtractive cloning screen for novel AD candidate genes. We identified the gene encoding the
DNA replication factor CIZ1 (CDKN1A interacting zinc finger protein 1) as being more highly expressed in
Alzheimer tissue than in healthy brains. We show here that an isoform of CIZ1 which lacks a glutamine-rich
region, due to alternative splicing in exon 8, is upregulated in AD brains relative to the full-length CIZ1
protein. We demonstrate for the first time that a minimal 28 amino acid sequence within this region is
required for CIZ1 to associate with the nuclear matrix and to form nuclear foci.
© 2008 Elsevier Inc. All rights reserved.IntroductionAlzheimer's Disease (AD) is a debilitating disease, characterised by
the progressive loss of memory and cognitive abilities. Neuropatholo-
gically, the disorder is associated with the extracellular deposition of
β-amyloid aggregates in senile plaques and the intracellular accumula-
tion of neurofibrillary tangles. These changes lead to the loss of synaptic
function and neuronal cell death in specific brain regions (Terry et al.,
1999). The first regions affected by neuronal loss and AD pathology
include theentorhinal cortex and theCA1 subregionof thehippocampus
(Braak and Braak, 1991; Gomez-Isla et al., 1996;West et al., 1994). Since
these regions are essential for the flow and integration of information
through the hippocampus, this explains why the early symptoms of AD
are related to defective memory (Eichenbaum, 2001; Morris, 1999).
Genetically inherited mutations which lead to early-onset AD
(onset before the age of 60) have so far been identified in three genes:
amyloid precursor protein, presenilin 1 and presenilin 2 (Price and
Sisodia, 1998; Sisodia et al., 1999). However, early-onset AD comprises
only about 5% of AD cases. The majority of AD cases are late-onset
(after 65 years of age), and occur sporadically. Several genetic risk
factors have been described for the late-onset form of AD, notably the
ɛ4 allele of the apolipoprotein E gene (Corder et al., 1993; Farrer et al.,r protein 1; CDKN1A, Cyclin-
er's disease; GAPDH, Glycer-
family member 2; GFAP, glial
l rights reserved.1997; Saunders et al., 1993), but the precise etiology of sporadic AD is
poorly understood.
Several reports have indicated that the inappropriate re-entry of
post-mitotic neurons into the cell cycle may lead to disruption of cell
function in AD (Nagy, 2000; Zhu et al., 2006). In addition to elevated
levels of cell cycle proteins, there is evidence that AD-affected neurons
have passed the G1/S-checkpoint and initiated DNA replication
(Vincent et al., 1997; Yang et al., 2001, 2003). CDKN1A (p21Cip1) is a
major factor in blocking the onset of S phase. CIZ1 was first isolated in
a yeast two-hybrid screen for cyclin E/CDKN1A interaction partners
and shown to bind to CDKN1A (Mitsui et al., 1999). It was proposed
that CIZ1 regulates entry into S phase by inducing the cytoplasmic
export of CDKN1A (Mitsui et al., 1999). CIZ1 contains two glutamine-
rich domains in the N-terminal end, and three zinc fingers in the
C-terminal end which are capable of binding to DNA (Mitsui et al.,
1999; Warder and Keherly, 2003). Murine Ciz1 has been shown to
stimulate DNA replication in NIH3T3 cells. Consistent with a role in
DNA replication, Ciz1 forms nuclear speckles, and colocalises with
PCNA in replication foci during S phase (Coverley et al., 2005).
There is currently no effective therapy preventing cell loss in AD.
Identification of genes whose expression is altered during the be-
ginning stages of the disease should aid in identifying molecules that
are potential targets for therapy and lead to a better understanding of
the disease process. Using a subtractive cloning approach, we pre-
viously reported the identification of NDRG familymember 2 (NDRG2)
as a protein upregulated in AD and associated with AD pathology
(Mitchelmore et al., 2004). Here, we describe additional candidate
genes, isolated in the same screen, which are upregulated in AD. Of
these, the gene encoding CDKN1A interacting zinc finger protein 1
Fig. 1. Expression analysis of AD candidate genes on a slot blot. Plasmid DNA containing
the indicated cDNAs were slot-blotted onto a membrane in duplicate. The membrane
was cut in half and probed separately with radioactively labeled cDNA from either
normal adult hippocampus (left) or AD hippocampus (right). Results were quantified by
phosphorimager analysis and normalised to GAPDH. Eleven genes were found to be
upregulated by at least 2-fold in this assay (starred).
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replication factor.
Results
Identification of genes upregulated in AD brains
Using a subtractive cloning technique to detect candidate genes
upregulated in the hippocampal region of AD brains, we previously
isolated a total of 42 cDNAs (Mitchelmore et al., 2004). In order to test
the remaining uncharacterised candidate genes for upregulation, we
used a slot blot approach where plasmid DNA containing cDNA inserts
were separately hybridised with labelled cDNA probe prepared from
either control or AD hippocampus mRNA (Fig. 1). Changes in gene
expression that are related to AD are expected to be highest in theFig. 2. Altered expression of CIZ1S is observed in AD hippocampus. PCRwas used to examine
exception of AD, the short CIZ1S splice form was expressed at a lower level than the full-lenhippocampus, which is one of the brain regions most affected by AD
pathology (Braak and Braak, 1991; West et al., 1994). GAPDH mRNA
levels are unchanged in AD, allowing its use as a normalisation control
(Gutala and Reddy, 2004). After normalisation of the signal to GAPDH,
we identified 10 new candidate genes whose expression was
upregulated in AD by more than 2-fold compared to control
hippocampus. Upregulation of the mRNAs for NDRG2 and GFAP in
AD confirms our previous results (Mitchelmore et al., 2004), whereas
upregulation of the polyadenylated form of mitochondrial 16S
ribosomal RNA (MTRNR2) is probably a result of the increased
mitochondrial DNA observed in AD (Hirai et al., 2001). Polyadenyla-
tion of themitochondrial 16S ribosomal RNA and highly related cDNAs
have previously been observed (Baserga et al., 1985; Guo et al., 2003).
The results of the slot blot should be considered semiquantitative, due
to variations inherent in any hybridization reaction, the high
complexity of cDNA probes, and to detection limitations for low
abundance genes (Wang and Brown, 1991).
In order to confirm the slot blot results, we selected two of the
novel AD candidates to determine expression levels in human brain
RNA distinct from that used in the subtractive cloning. In contrast to
the slot blot, northern blotting was carried out onwhole brain RNA. By
northern blotting, we showed a modest (25% and 23%, respectively)
increase in the mRNA levels for EFNA3 and CIZ1, respectively, in AD
compared to normal brain (data not shown). Since inappropriate entry
into the cell cycle may play a role in AD (Nagy, 2000) and CIZ1 can act
as a DNA replication factor (Coverley et al., 2005), we decided to
examine CIZ1 tissue expression and cellular localisation in more
detail.
Differential expression of CIZ1 splice forms in AD brain
CIZ1 mRNA expression was examined in normal and AD afflicted
tissue as well as in a range of human tissues and cell lines by PCR
amplification of the region surrounding exon 8. As shown in Fig. 2, the
splice variant CIZ1S, which contains a 168 nt deletion in exon 8, is
upregulated in AD compared to normal hippocampi, taking into
consideration the different levels of GADPH, used for normalisation, in
the two tissues. Quantification of the data in Fig. 2 shows that levels of
the full-length CIZ1 are unaltered in AD, whereas expression of the
splice variant CIZ1S is upregulated 2.5-fold in AD compared to normal
hippocampus, after normalisation to GAPDH. As expected, GFAP
expression is increased in AD compared to normal hippocampus, by
5.6-fold, due to astrogliosis (Diedrich et al., 1987).
In AD hippocampus, CIZ1S expression is comparable to that of full-
length CIZ1. In contrast, expression of CIZ1S is distinctly lower than
the full-length transcript in all the examined normal tissues and cell
lines. Amongst the cell lines, CIZ1 was more highly expressed in the
Ad5-transformed HEK293 and MCF7 cell lines, and was undetectable
in the U118 glioblastoma cell line. Alternative splicing in exon 8 results
in the in-frame removal of 56 amino acids (CIZ1S) or 28 amino acidsalternative splicing of exon 8 in AD hippocampus, normal tissues and cell-lines. With the
gth CIZ1 form in all samples. HF, hippocampus.
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transcripts with the shorter deletion in exon 8 were not detected,
probably due to a very low mRNA expression.
Association of CIZ1 with the nuclear matrix requires a glutamine-rich
domain
In order to examine the importance of alternative splicing in exon
8 for the subcellular localisation of CIZ1 protein, we attempted to
amplify the coding region of CIZ1 from hippocampus and cerebellum,
where both CIZ1 and CIZ1S are expressed (see Fig. 2). However, we
were unable to clone the coding region of CIZ1S, although we did
obtain clones for both CIZ1 and CIZ1M. Mouse N2A neuroblastoma
cells were therefore transfected with expression plasmids for full-
length CIZ1 and the shorter isoform CIZ1M (Fig. 3A).
Cell lysates were separated into four fractions: soluble proteins,
two fractions of chromatin-bound proteins, and proteins bound to the
nuclear matrix. Both CIZ1 and CIZ1M proteins appeared in the soluble
fraction and the DNase-treated chromatin fraction. However, the
majority of full-length CIZ1 protein was recovered in the nuclear
matrix fraction. Deletion of 28 amino acids in the glutamine-rich Q2-
region almost completely abrogated association of CIZ1M with the
nuclear matrix (Fig. 3B).
In accordance with the fractionation results, immunofluorescent
staining of the transfected cells showed that full-length CIZ1 protein
appeared in speckles which resemble replication foci (Figs. 4A–C).
However, in some cells CIZ1 appeared to be localized mainly in the
cytoplasm, where it might be sequestered when it is not involved in
DNA replication (Figs. 4D–F). The smaller splice variant CIZ1M did not
form the speckled pattern, but instead it localized solely in the nucleus
in a diffuse pattern (Figs. 4G–I). Therefore, the region lacking in CIZ1M
seems to be important for the location and appearance of CIZ1 in theFig. 3. (A) The structure of full-length CIZ1 is shown. The residues lacking in the human
splice variants CIZ1M and CIZ1S, due to alternative splicing in exon 8, are indicated. The
168 bp deletion is present in cDNAs with accession nos. BC021163 and AK023976; the
shorter 84 bp deletion is present in BC004119 and CIZ1M (this study). For comparison,
the homologous region deleted in the mouse ECiz1 isoform (Coverley et al., 2005), due
to alternative splicing, is shown. (B) Western blot of V5-tagged CIZ1 (left panel) and
CIZ1M (right panel) in fractions obtained from transfected cells: soluble proteins
(nuclear and cytoplasmic), chromatin-bound proteins (DNase- or NaCl-released) and
nuclear matrix-bound proteins. The proteins lamin A/C, α-tubulin and histone H3 are
released in different fractions and demonstrate the purity of the fractions. The majority
of the full-length CIZ1 is present in the nuclear matrix, whereas CIZ1M is mostly present
in the soluble and chromatin fractions. The results are representative of three
independent experiments.cell. Since this region is also lacking in the CIZ1S variant, it is likely that
the pattern of CIZ1S resembles that shown here for CIZ1M.
Discussion
In this study, we demonstrate the altered processing of CIZ1mRNA
in the hippocampus of AD patients. This results in the upregulation of
an alternatively spliced form of CIZ1, in which the encoded protein
lacks a glutamine-rich domain. This smaller transcript, CIZ1S, is pre-
sent as a minor component in a range of normal tissues and cancer cell
lines, suggesting that the ratio of CIZ1S to the full-length CIZ1 is
normally regulated. Misregulation of alternative splicing has pre-
viously been reported for sporadic AD, including exon 5 skipping for
the Presenilin-2 transcript and exon 10 inclusion in the Tau transcript
(Glatz et al., 2006; Manabe et al., 2003). Misregulation of splicing in
AD may be a result of genetic mutations in the gene itself or reflect
changes in the regulators of splicing, for example as a result of hypoxic
stress (Manabe et al., 2003). In the case of CIZ1S, a 168 nt region
located centrally in exon 8 is spliced out. Although the “intron” con-
forms to the GT–AG rule, there is no polypyridine tract, and the
mechanism regulating alternative splicing in exon 8 is unclear.
Our results demonstrate that the majority of full-length human
CIZ1 protein is bound to the nuclear matrix, following extraction with
nuclease and high salt. Accordingly, our immunofluorescent staining
revealed the localisation of CIZ1 in nuclear speckles. This is in agree-
ment with results obtained with endogenous mouse Ciz1, in which
nuclear-matrix-associated Ciz1 is present in replication foci (Ain-
scough et al., 2007). Our observation that some CIZ1 is released by
nuclease treatment is consistentwith the role of CIZ1 as aDNA-binding
protein (den Hollander et al., 2006; Warder and Keherly, 2003).
Furthermore, we observe a proportion of CIZ1 in the soluble fraction,
consistent with reports that mouse Ciz1 is present in the nucleus as
both a soluble and a detergent-resistent fraction (Coverley et al., 2005).
We also observe formation of CIZ1 aggregates in the cytosol of some
transfected cells. This may result from self-aggregation of CIZ1, due to
its glutamine-rich domains, or to the cytoplasmic sequestration by
CIZ1 of cell cycle proteins such as CDKN1A (Mitsui et al., 1999).
Alternative splicing in CIZ1S results in the removal of amino
acids 379–434 in the second glutamine-rich domain. Deletion of a
corresponding region by alternative splicing has been reported in
the embryonic form of mouse Ciz1, called ECiz1 (Coverley et al.,
2005) (Fig. 3). We used a transcript with a shorter deletion within
exon 8 in cell transfection studies, in order to delineate the role of
this region in CIZ1 localisation, since we were unable to clone CIZ1S
by PCR. The 28 amino acid region lacking in CIZ1M is also lacking in
CIZ1S, and therefore we postulate that the appearance and
localisation of CIZ1S resembles that of CIZ1M. However, we cannot
exclude the possibility that the larger deletion in CIZ1S, removing
56 amino acids in the glutamine-rich domain of CIZ1, causes
additional changes in protein localisation. The CIZ1M variant,
lacking amino acids 407–434, showed a disruption of the speckled
pattern, and instead a diffuse localization in the nucleus was
observed. Furthermore, the CIZ1M protein was readily extracted into
the soluble and chromatin fractions, and only weakly associated
with the nuclear matrix in our fractionation studies. Ainscough and
others carried out immunofluorescence staining with NIH3T3 cells
and GFP-tagged ECiz1 (Ainscough et al., 2007). They demonstrated
that ECiz1 is less efficiently concentrated in nuclear foci than full-
length Ciz1. However, in contrast to our results with CIZ1M, they
showed that GFP-ECiz1 resists extraction with detergent and
nuclease/high-salt, indicating attachment to the nuclear matrix.
They conclude that sequences in the C-terminal third of Ciz1 are
responsible for immobilization on the nuclear matrix. However,
these results cannot be directly compared to ours, because they use
a GFP tag and a milder 0.5 M NaCl extraction, either of which may
affect subnuclear attachment.
Table 1
Description of the cDNAs isolated in a screen for AD-upregulated genes and analysed by
slot blot
Gene mRNA Insert⁎ Full name Accession
no.
EFNA3 1798 nt 1.8 kb Ephrin-A3 NM_004952
MAPT 5464 nt 570 bp Microtubule-associated protein tau NM_016841
SRP72 3852 nt 2 kb Signal recognition particle 72 kDa NM_006947
SEPT5 2079 nt 1.8 kb Septin 5 BC025261
CIZ1 3032 nt 2.1 kb CDKN1A interacting zinc finger protein 1 NM_012127
ATRN 8645 nt 1.8 kb Attractin NM_139321
HTRA1 2133 nt 2.1 kb HtrA serine peptidase NM_002775
MTRNR2 1558 nt 600 bp Mitochondrial 16S rRNA EU369395
RGL1 5113 nt 2.8 kb Ral guanine nucleotide dissociation
stimulator-like 1
NM_015149
JARID1A 6455 nt 1.8 kb Jumonji, AT rich interactive domain 1A NM_005056
NELF 2972 nt 2.9 kb Nasal embryonic LHRH factor NM_015537
AUTS2 5972 nt 1.7 kb Autism susceptibility candidate 2 NM_015570
HSP90AA1 2912 nt 2.9 kb Heat shock protein 90 kDa alpha
(cytosolic), class A member 1
NM_005348
VSNL1 2014 nt 2.2 kb Visinin-like 1 NM_003385
PLP1 3038 nt 3 kb Proteolipid protein 1 NM_000533
GLUL 2778 nt 2.7 kb Glutamate-ammonia ligase BC011700
HSPA8 2276 nt 2.1 kb Heat shock 70 kDa protein 8 NM_006597
⁎All cDNA inserts contained a 3′ poly-A tail, except SRP72, RGL1, JARID1A (due to
mispriming at an internal A-rich sequence) and CIZ1 (due to cleavage at an internal NotI
site).
Fig. 4. Subcellular localization of V5-tagged CIZ1 isoforms. Staining for the full-length variant of CIZ1 showed a speckled pattern, localized in varying patterns: in the nucleus (A),
cytosol (D) or both (not shown). The CIZ1Mvariant lacking part of the second polyglutamine domainwas diffusely distributed throughout the nucleus (G). (A, D, G) V5 staining; (B, E, H)
DAPI staining; (C, F, I) merged images.
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cells: 95 and 120 kDa in human, and 100 and 125 kDa in mouse cells
(Coverley et al., 2005; Mitsui et al., 1999). In human U2-OS cells, the
95 kDa species is detergent-soluble whereas the 120 kDa form of CIZ1
fractionates in the NP-40 resistant cell pellet (Mitsui et al., 1999).
However, in NIH3T3 cells, the p100 form of Ciz1, but not the p125
form, is resistant to 2 M NaCl extraction, suggesting a stronger
association of the p100 form with subnuclear structures (Ainscough
et al., 2007). These differences may reflect the different detergent
treatments and cell lines used. It may also suggest that there are
differences in the behaviour of mouse and human CIZ1, which share
only about 70% homology. The relation between the 95 and 120 kDa
protein species is currently unclear. However, the larger 120 kDa
species behaves like full-length CIZ1 does in our hands, whereas the
95 kDa protein in human cells and CIZ1M are both detergent-soluble.
The 28 amino acid region lacking in CIZ1M is also lacking in CIZ1S, and
therefore we postulate that CIZ1M and CIZ1S behave similarly. Thus,
the 95 kDa form may arise from alternative splicing in exon 8 and
thereby generating an isoform lacking part of the second glutamine-
rich domain, corresponding to either CIZ1M or CIZ1S.
We demonstrate for the first time that human CIZ1 associates with
the nuclear matrix. Furthermore, we report that in human CIZ1, amino
acids 407–434 affect the formation of speckles and attachment to the
nuclear matrix. Since this exon 8-encoded region is also lacking in the
CIZ1S variant, we postulate that the appearance and localisation of
CIZ1S resembles that of CIZ1M. Mouse ECiz1 retains the ability to
promote DNA replication, suggesting that exon 8 is not required for
this basic function (Coverley et al., 2005). There are 4 binding regions
for CDKN1A on CIZ1: one between the two glutamine-rich domains,two in the zinc finger region, and one in the C-terminal end (Mitsui
et al., 1999). Since these regions are outside of the regions deleted in
CIZ1M and CIZ1S, it is likely that CIZ1M and CIZ1S also bind to
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mation, by tethering replication factories to the nuclear matrix
(Ainscough et al., 2007). Thus, assembly of CIZ1 into nuclear foci is
likely to be important for regulated entry into the S-phase of the cell
cycle. The increased expression of CIZ1S compared to CIZ1 in AD may
therefore be expected to contribute to disregulation of cell cycle
control.
Experimental methods
Slot blot
A 1 kb PCR product for human GAPDH cDNA was cloned into the
pCR-TOPO vector (Invitrogen). The other plasmids used in the slot blot,
containing cDNA inserts in the pZL1 plasmid (Invitrogen), were
isolated in a subtractive screen for genes upregulated in AD
(Mitchelmore et al., 2004; Table 1). Plasmid DNA (1 μg) was denatured
in 0.3 M NaOH for 10 min at 68 °C, neutralised and bound in duplicate
to a Hybond-XL membrane in a slot–blot vacuum apparatus. The
membrane was cut in half and the duplicate blots were separately
hybridised to radioactively labelled first-strand cDNA (100 ng) which
had been prepared from either AD or control hippocampus RNA
(Mitchelmore et al., 2004). To block non-specific binding, the
hybridisation buffers contained 500 μg denatured salmon sperm
DNA and 5 μg poly-dT20, and the overnight hybridisation was carried
out at 72 °C. Stringent hybridisation andwash conditions were used to
reduce cross-hybridisation with related sequences. Bound label was
quantified with a phosphorimager.
RT-PCR
cDNA synthesis on U118 mRNA was performed using SuperScript
III Reverse Transcriptase Kit (Invitrogen). First-strand cDNA from liver
and colon, Marathon cDNA from cerebellum and hippocampus, and
cDNA from a human cell line panel were all purchased from Clontech.
The 25 μl PCR reaction contained 2.5 μl cDNA, 10 pmol each primer,
2.5 μl reaction buffer, 0.2 M dNTPs and 0.5 μl Advantage II Polymerase
(Clontech). The PCR program was: 1 cycle at 94 °C; 5 cycles at 94 °C
30 s, 72 °C 2min; 15–25 cycles at 94 °C 30 s, 68 °C 2min; and 1 cycle at
68 °C 5 min.
The following primer pairs were used in PCR: CIZ1 (5′ GTACCGAAA-
CAGACACAGACACCAGAC 3′ and 5′ AACCACAACTGGTGTTTGCTCTGGAG
3′); GAPDH (5′ TGAAGGTCGGAGTCAACGCATTTGGT 3′ and 5′
CATGTGGGCCATGAGGTCCACCAC 3′); and GFAP (5′ TGACCCTCTCCACCC-
CATAGTGAC 3′ and 5′ CTAATCTTCAGGGCACTGCTGCTG 3′). The expected
fragment sizes were: GAPDH 983 bp, GFAP 424 bp, CIZ1 585 bp, CIZ1M
501 bp and CIZ1S 417 bp. The identity of the PCR bands obtained for CIZ1
were confirmed by sequencing.
Cell transfections
The coding region of CIZ1 was obtained by PCR amplification from
cerebellum cDNA and cloned into the pcDNA6/V5HisA vector
(Invitrogen), in frame with the C-terminal V5-epitope. The inserts
were completely sequenced, and shown to encode full-length CIZ1 as
well as the CIZ1M splice variant. Mouse neuroblastoma (N2A) cells
were grown in Dulbecco's modified Eagle's medium containing 10%
FBS with penicillin/streptomycin. 2.5×105 cells/well were seeded in a
6-well plate, transfected with 4 μg DNA per well using Lipofectamine
2000 (Invitrogen), and harvested after 48 h.
Immunocytochemistry
2×104 cells were grown on coverslips in 24-well plates for 24 h
before transfection, and then grown for 48 h before being fixed in cold
methanol for 5 min. Cells were blocked in PBS containing 0.2% TritonX-100 and 3% BSA and washed in PBS with 0.2% Triton X-100. Mouse
anti-V5 antibody (Invitrogen) was diluted 1:400, incubated overnight
on the coverslips in a humidity chamber at 4 °C, and was detected
using Alexa Fluor 488 anti-mouse antibody. Coverslips were mounted
onto slides using Vectashield mounting medium with DAPI (Vector).
Images were collected using a Leica FW 4000 camera with a 100× oil
objective.
Cell fractionation and western blots
The protocol is adapted from (Farley et al., 2006; He et al., 1990).
Cell pellets were washed twice in PBS and centrifuged 5 min at
2000 rpm. The cell pellet was resuspended in cold cytoskeletal
(CSK) buffer (20 mM PIPES (Sigma), 100 mM NaCl, 300 mM Sucrose,
3 mM MgCl2, 1 mM EGTA (Sigma), protease inhibitor (1:500 v/v)
(Sigma), 0.5% Triton X, pH 7), incubated at room temperature for
5 min and centrifuged 5 min at 2000 rpm. The supernatant was
collected and labeled “Soluble fraction”. This step was repeated
once, and the pellet was resuspended in CSK buffer containing
250 U/ml DNase I (Roche) and incubated 15 min at 20 °C, followed
by 20 min at 37°C. Then (NH4)2SO4 was added to give a final
concentration of 0.25 M, and the samples were incubated 5 min on
ice. Hereafter the samples were centrifuged at 8000 rpm for 5 min.
The supernatant was collected and labeled “Chromatin DNase
fraction”. The pellet was then resuspended in CSK buffer containing
2 M NaCl, incubated 5 min on ice, and centrifuged 5 min at
13,000 rpm. The supernatant was collected and labeled “Chromatin
NaCl fraction”. The remaining pellet was resuspended in 8 M urea
solution (8 M urea pH 8, 100 mM NaH2PO4, 10 mM Tris–HCl), and
labeled “Nuclear Matrix fraction”.
Protein concentration was measured using the Bradford assay.
Proteins were separated on 4–12% Tris–Glycine SDS gels (Anamed),
and transferred to PVDFmembranes (GE Healthcare). Immunoblotting
was performed using the West Dura kit (Pierce). Primary antibodies
were diluted as follows: anti-V5 (1:20,000), mouse anti-α-tubulin and
rabbit anti-histone H3 (1:10,000, Sigma); and rabbit anti-lamin A/C
(1:4000, Cell Signaling Technology). Protein bands were detected
using a Biospectrum AC imaging System (UVP).
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